Adagene (ADAG) Liabilities and Shareholders Equity (2019 - 2026)
Adagene (ADAG) posted quarterly Liabilities and Shareholders Equity of $78.3 million for Q4 2025, down 12.33% year-over-year from $89.3 million in Q4 2024, and up 17.66% quarter-over-quarter from $66.5 million in Q2 2025.
Analysis
Adagene (ADAG) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $78.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 12.33% year-over-year to $78.3 million; the TTM figure through Dec 2025 stood at $334.8 million (up 9.5% YoY), while the FY2025 annual figure was $78.3 million, down 12.33% from the prior year.
- Liabilities and Shareholders Equity climbed to $78.3 million in Q4 2025 per ADAG's latest filing, from $66.5 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $217.9 million in Q2 2021 and bottomed at $135.3 in Q2 2023.
- Historically, Liabilities and Shareholders Equity has averaged $101.0 million across 5 years, with a median of $95.0 million in 2024.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 100.0% — and 2024, when it jumped 74484683.94%.
- Adagene's Liabilities and Shareholders Equity stood at $189.5 million in 2021, then declined by 19.58% to $152.4 million in 2022, then retreated by 24.06% to $115.7 million in 2023, then retreated by 22.86% to $89.3 million in 2024, then slipped by 12.33% to $78.3 million in 2025.
- Business Quant data shows ADAG's Liabilities and Shareholders Equity at $78.3 million in Q4 2025, $66.5 million in Q2 2025, and $89.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - | 133.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 133.58 Mn |
| Dec 31, 2025 | 78.26 Mn |
| Jun 30, 2025 | 66.52 Mn |
| Dec 31, 2024 | 89.27 Mn |
| Jun 30, 2024 | 100.78 Mn |
| Dec 31, 2023 | 115.73 Mn |
| Jun 30, 2023 | 135.30 Mn |
| Dec 31, 2022 | 152.40 Mn |
| Jun 30, 2022 | 178.56 Mn |
| Dec 31, 2021 | 189.51 Mn |
| Jun 30, 2021 | 217.86 Mn |
| Dec 31, 2020 | 84.26 Mn |
| Dec 31, 2019 | 105.89 Mn |